ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Bought by Cwm LLC

Cwm LLC increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 72.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,129 shares of the biotechnology company’s stock after acquiring an additional 5,937 shares during the period. Cwm LLC’s holdings in ADMA Biologics were worth $282,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in ADMA Biologics during the 2nd quarter worth $29,000. EntryPoint Capital LLC bought a new position in shares of ADMA Biologics during the 1st quarter valued at about $31,000. Acadian Asset Management LLC bought a new stake in shares of ADMA Biologics in the 2nd quarter worth approximately $93,000. Viewpoint Capital Management LLC raised its holdings in shares of ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 2,416 shares in the last quarter. Finally, Xponance Inc. boosted its holdings in ADMA Biologics by 43.5% during the second quarter. Xponance Inc. now owns 18,468 shares of the biotechnology company’s stock worth $206,000 after buying an additional 5,597 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 1.0 %

ADMA stock opened at $15.62 on Tuesday. The company has a 50 day moving average of $18.07 and a two-hundred day moving average of $12.80. The company has a market cap of $3.62 billion, a price-to-earnings ratio of -781.00 and a beta of 0.62. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $21.13. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same period in the previous year, the firm posted ($0.02) earnings per share. The company’s revenue for the quarter was up 78.4% compared to the same quarter last year. On average, equities analysts anticipate that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the transaction, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ADMA. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of ADMA Biologics in a report on Monday, October 14th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.